G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Total Current Assets
kr180m
CAGR 3-Years
35%
CAGR 5-Years
42%
CAGR 10-Years
23%
AddLife AB
STO:ALIF B
Total Current Assets
kr3.6B
CAGR 3-Years
29%
CAGR 5-Years
28%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Total Current Assets
kr2B
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Total Current Assets
kr1.2B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
16%
MedCap AB (publ)
STO:MCAP
Total Current Assets
kr873.7m
CAGR 3-Years
25%
CAGR 5-Years
29%
CAGR 10-Years
10%
M
Magle Chemoswed Holding AB
STO:MAGLE
Total Current Assets
kr79.2m
CAGR 3-Years
7%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Total Current Assets?
Total Current Assets
180m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Total Current Assets amounts to 180m SEK.

What is Genovis AB's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
23%

Over the last year, the Total Current Assets growth was 15%. The average annual Total Current Assets growth rates for Genovis AB have been 35% over the past three years , 42% over the past five years , and 23% over the past ten years .

Back to Top